Post-Conference Highlights | 2026 ViVE | Feb 22–25 | Los Angeles, CA

Why It Matters

The focus on execution, data liquidity, and accountable investment reshapes how payers, providers, and tech firms allocate capital, directly influencing the speed and scale of healthcare transformation.

Key Takeaways

• AI adoption now requires governance, ROI, and trust.
• Interoperability becomes core infrastructure for data liquidity.
• $50B rural health funds aim to shift care home‑based.
• Precision medicine pushes for scalable genomic integration.
• Policy and investment align to accelerate accountable digital health.

Pulse Analysis

The narrative emerging from ViVE 2026 underscores a maturation of digital health that goes beyond hype to disciplined execution. AI tools, once celebrated for novelty, are now judged on governance frameworks, explainability, and demonstrable return on investment. Executives from health systems and cloud providers highlighted the need for integrated workflows where AI augments clinical decision‑making rather than operating in isolation. This shift is prompting vendors to embed robust validation processes and to align product roadmaps with measurable outcomes, accelerating adoption in revenue‑sensitive environments.

Interoperability took center stage as the foundational layer enabling the next wave of innovation. Sessions on patient data supply and demand revealed persistent information blocking, prompting calls for operational transparency that surpass regulatory compliance. Federal leaders outlined evolving standards that prioritize trust and security, while private‑sector players showcased platforms designed to unlock real‑time data exchange across imaging, pathology, and genomics. The resulting data liquidity is expected to power predictive analytics, reduce duplication, and support value‑based care models, positioning interoperable ecosystems as a competitive differentiator for health networks.

Policy and capital are converging to drive accountable transformation. ARPA‑H’s milestone‑driven funding model, coupled with a $50 billion rural health transformation program, illustrates a strategic alignment between government incentives and private‑sector execution. Simultaneously, investors are quantifying the economics of prevention and precision medicine, demanding evidence of cost avoidance and equitable outcomes. As these financing mechanisms mature, they will catalyze scalable solutions that integrate genomic data into everyday workflows and shift care delivery toward community‑based settings, cementing a new era of outcome‑focused healthcare.